Odds of Severe COVID-19 High for Hematologic Cancer Patients During Pandemic
By Elana Gotkine HealthDay Reporter
THURSDAY, Feb. 29, 2024 -- For patients with hematologic cancers, the odds of developing severe COVID-19 despite vaccination remained high through mid-2022, according to a study published online Feb. 23 in JAMA Network Open.
Sonia T. Anand, Ph.D., M.P.H., from the VA Boston Cooperative Studies Program, and colleagues conducted a case-control study including all patients with hematologic malignant neoplasms in the national Veterans Health Administration with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after vaccination. Patients with severe COVID-19 (cases) versus nonsevere COVID-19 (controls) were compared; data were included for 6,122 patients, 21.3 percent of whom had severe COVID-19.
The researchers found that the odds of severe disease were higher in association with age (adjusted odds ratio [aOR] per one-year increase, 1.05), treatment with antineoplastic or immune-suppressive drugs (e.g., in combination with glucocorticoids: aOR, 2.32), and comorbidities (aOR per comorbidity, 1.35). Booster vaccination was associated with lower odds of severe disease. Overall, 3.7 percent of patients with SARS-CoV-2 infection during the period after oral antiviral drugs became widely used in March 2022 had progression to severe COVID-19.
"Although the magnitude of benefit of antiviral treatments during nonsevere disease could not be quantified, the relatively low proportion of treated patients who developed severe COVID-19 is sufficient to promote greater use," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Further Support and Information on COVID-19
Read this next
ASCO: Asciminib Has Superior Efficacy to TKIs for Newly Diagnosed Leukemia
WEDNESDAY, June 5, 2024 -- For patients with newly diagnosed chronic myeloid leukemia (CML), asciminib shows superior efficacy and a favorable safety profile compared with...
No Decline in Cardiovascular Events Seen With COVID-19 Vaccine After Acute Coronary Syndromes
MONDAY, June 3, 2024 -- Patients who have received at least one COVID-19 vaccine dose after acute coronary syndromes do not have a reduced risk for cardiovascular events...
At-School Vaccination Boosts HPV Vaccination Coverage
THURSDAY, May 30, 2024 -- At-school vaccination may be a useful tool to increase human papillomavirus (HPV) vaccination coverage among adolescents, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.